Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on May 16, 2022 12:04pm
224 Views
Post# 34686449

Institutional Holdings Update

Institutional Holdings UpdateAccording to Bloomberg, Soleus has not yet posted its updated holdings of THTX thru 3/31/22. Soleus' stock holdings have been hit hard (assuming they did not get out early) so far in 2022 and that raises concerns about Soleus getting fired by some of its institutional clients (they should be giving new money to Soleus on weakness but that normally is not how things go). Alternatively, because THTX has not performed as badly, it is now likely a larger holding in their portfolios and they might feel a need to trim it a bit. Hopefully, we will know tomorrow when we presume the filing will be updated on Bloomberg.

As pointed out earlier by Louis, Morgan Stanley added 1.4 million shares. Caisse de Depot sold the remaining 300,000+ shares they owned during the first quarter. Most of the other changes were small and were mostly biased to the buy side.
<< Previous
Bullboard Posts
Next >>